Phenotype variability and therapeutic response to Patisiran in patients with hereditary transthyretin amyloidosis: a Belgian real-world experience
Open Access
- 1 November 2024
- journal article
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 79 (6) , 393-402
Abstract
Hereditary transthyretin amyloidosis (hATTRv) is a rare, genetic, adult-onset, multisystemic disorder which can affect diverse organs, including peripheral nerves, heart, kidneys, gastrointestinal tract, liver, skin and eyes. Currently, several disease-modifying treatments for hATTRv are available in Belgium including the TTR stabilizer tafamidis and TTR mRNA silencers patisiran and vutrisiran. Patisiran contains a small interfering RNA encapsulated into a lipid nanoparticle to deliver to hepatocytes, the main source of TTR protein production, thereby reducing TTR production. We report and discuss five cases of hATTRv in different clinical scenarios that were successfully managed with patisiran, highlighting our real-world clinical practice. These cases illustrate that patisiran is effective to improve mild symptoms and stabilize the moderate ones. The cases also highlight the importance of red flags recognition to allow early diagnosis and treatment to prevent further disease progression. Due to the multisystemic nature of the disease and its heterogeneous clinical presentation, close collaboration between neurologists and cardiologists is highly recommended, ideally within a multidisciplinary amyloidosis team, to provide holistic care in hATTRv patients.Keywords
Funding Information
- Alnylam
This publication has 40 references indexed in Scilit:
- Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapiesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2021
- Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology W orking G roup on M yocardial and P ericardial D iseasesEuropean Journal of Heart Failure, 2021
- Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awarenessHeart Failure Reviews, 2021
- Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literatureJournal of Neurology, 2020
- Carpal Tunnel Syndrome in Cardiac Amyloidosis: Implications for Early Diagnosis and Prognostic Role Across the Spectrum of AetiologiesEuropean Journal of Heart Failure, 2020
- Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathyJournal of Neurology, 2020
- Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis)Clinical Autonomic Research, 2018
- Liver transplantation in transthyretin amyloidosis: Issues and challengesLiver Transplantation, 2015
- Amyloid NeuropathiesMount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2012
- Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathyMuscle & Nerve, 2011